Development of sarcoidosis following etanercept treatment: a report of three cases
- 9 January 2010
- journal article
- case report
- Published by Springer Science and Business Media LLC in Rheumatology International
- Vol. 32 (4), 1049-1053
- https://doi.org/10.1007/s00296-009-1349-x
Abstract
After over 10 years of use of tumor necrosis factor-alpha (TNF-α) inhibitors, their side effects and complications are reasonably well documented. Recently, however, granulomatous reactions and cases of complete sarcoidosis have been reported, especially in patients treated with the TNF-α receptor protein, etanercept. This is intriguing because the TNF-α antibody drugs infliximab and adalimumab are reportedly used to treat sarcoidosis. We present three patients who developed sarcoidosis while on etanercept treatment, and discuss if possible differences in cytokine profiles and T regulatory cell function in patients taking different TNF-α inhibitors may explain this paradox.Keywords
This publication has 41 references indexed in Scilit:
- Promoting science over serendipity in prescribing anti-TNF therapyRheumatology, 2009
- Analysis of regulatory T cell associated forkhead box P3 expression in the lungs of patients with sarcoidosisClinical and Experimental Immunology, 2008
- Relapse of sarcoidosis upon treatment with etanerceptAnnals Of The Rheumatic Diseases, 2008
- SarcoidosisNew England Journal of Medicine, 2007
- Pulmonary sarcoidosis developing during infliximab therapyArthritis Care & Research, 2006
- Interferon-Induced SarcoidosisJCR: Journal of Clinical Rheumatology, 2006
- TNF downmodulates the function of human CD4+CD25hi T-regulatory cellsBlood, 2006
- Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα TherapyThe Journal of Experimental Medicine, 2004
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseNew England Journal of Medicine, 2004
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001